Bank of America has revised its price target for Acadia Pharmaceuticals (ACAD, Financial), reducing it slightly from $19 to $18. Despite this adjustment, the bank maintains a Neutral rating on the biotech company's shares.
This decision is part of a broader review by the firm, updating its models on small- and mid-cap biotech companies ahead of their first-quarter earnings announcements. Investors and analysts are keeping a close watch on these updates as they assess prospects in the biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for ACADIA Pharmaceuticals Inc (ACAD, Financial) is $24.61 with a high estimate of $37.00 and a low estimate of $11.00. The average target implies an upside of 67.08% from the current price of $14.73. More detailed estimate data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, ACADIA Pharmaceuticals Inc's (ACAD, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ACADIA Pharmaceuticals Inc (ACAD, Financial) in one year is $35.98, suggesting a upside of 144.26% from the current price of $14.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Summary page.
